Differentiation between Israeli B. bovis vaccine strain and field isolates

- The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay based on rhoptry-associated protein-1 (rap-1) enabled differentiation between the Israeli vaccine strain and field isolates.
- Alignment of Israeli RAP-1-deduced amino acids of Israeli B. bovis strains and isolates showed that the total sequence identity among the amino acids of RAP-1 sequences ranged from 97.5% to 100%.
- A comparison between amino acids of RAP-1 of the Israeli vaccine strain and of field isolates and B. bovis strains from Argentina, Mexico, Brazil, and USA revealed 90% identity.

The present study demonstrated for the first time the ability to distinguish between the Israeli Babesia bovis vaccine strain and field isolates. The existence of an additional EcoRI restriction site in the rhoptry-associated protein-1 (rap-1) gene, which is unique to the Israeli vaccine strain, and the abolition of one of the HaeIII restriction sites in the rap-1 gene of the vaccine strain enabled distinction between the Israeli B. bovis vaccine strain and field isolates, and this was the basis for polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) development. ClustalW sequence alignment of RAP-1-deduced amino acids of the Israeli B. bovis strains and of field isolates showed that the total sequence identity among the RAP-1 amino acid sequences ranged from 97.5% to 100%. However, comparison between amino acids of RAP-1 of the Israeli vaccine strain and of field isolates, on the one hand, and B. bovis strains from Argentina, Mexico, Brazil, and USA, on the other hand, revealed 90% identity. The PCR-RFLP assay offered the great advantage of being able to distinguish between vaccine and field isolates in mixtures and provide new insight into the molecular epidemiology of B. bovis infections in Israel.